Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines.

Published

Journal Article

The efficacy and practical application of human immunodeficiency virus type 1 (HIV-1) vaccines may depend in part on the longevity of the immune responses generated, particularly those in the memory compartment. Candidate vaccines based on the HIV-1 envelope glycoproteins generate binding and neutralizing antibodies in humans but there have been no prior studies on the long-term persistence and recall of those responses. We evaluated six healthy, HIV non-infected adults who had received a combination of recombinant canarypox HIV-1 vaccines boosted by gp120 and who had achieved a high serum titer of neutralizing antibody to HIV-1 MN. These individuals were administered a gp160 boost 4-5 years after their last vaccination. Four volunteers had detectable binding and neutralizing antibodies at the time of boosting and all six volunteers exhibited a recall binding and neutralizing antibody response. The antibodies neutralized multiple T cell line-adapted (TCLA) strains of virus, including the vaccine strain, but not primary isolates. These results demonstrate that memory B-cell responses can last for many years following HIV-1 envelope glycoprotein immunization. In principle, similar long-term memory may be possible with improved immunogens that generate broadly cross-reactive neutralizing antibodies.

Full Text

Duke Authors

Cited Authors

  • Evans, TG; Frey, S; Israel, H; Chiu, J; El-Habib, R; Gilbert, P; Gaitan, A; Montefiori, DC; HIV Vaccine Trials Network (HVTN 803),

Published Date

  • June 2004

Published In

Volume / Issue

  • 22 / 20

Start / End Page

  • 2626 - 2630

PubMed ID

  • 15193388

Pubmed Central ID

  • 15193388

Electronic International Standard Serial Number (EISSN)

  • 1873-2518

International Standard Serial Number (ISSN)

  • 0264-410X

Digital Object Identifier (DOI)

  • 10.1016/j.vaccine.2003.12.011

Language

  • eng